If you are wondering whether Broadcom's current share price still reflects good value after its long run, or if the easier gains are already behind it, you are not alone in asking that question. Broadcom shares last closed at US$332.77, with returns of 4.1% over 7 days, 8.0% over 30 days, a 4.3% decline year to date, a very strong 72.2% return over the past year, an extremely high 3 year return, a...
If you are wondering whether Broadcom's current share price still reflects good value after its long run, or if the easier gains are already behind it, you are not alone in asking that question. Broadcom shares last closed at US$332.77, with returns of 4.1% over 7 days, 8.0% over 30 days, a 4.3% decline year to date, a very strong 72.2% return over the past year, an extremely high 3 year return, and a 5 year return of around 7x. Recent headlines around Broadcom have focused heavily on its role in key chip segments and its position in broader technology supply chains. This has kept investor attention firmly on the stock. This context helps explain why the share price has been so active recently, as the market weighs how those developments could influence long term expectations. On our checks, Broadcom scores 3 out of 6 on valuation, and you can see the breakdown in our . Next we will look at the different methods behind that result and then finish with a broader way to think about what fair value really means for this stock. Approach 1: Broadcom Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required return, to arrive at an estimate of what the business might be worth per share right now. For Broadcom, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is around $28.94b, and analyst and extrapolated projections suggest free cash flow could reach about $127.21b in 2030. Simply Wall St uses analyst forecasts where available, then extends those forecasts over a longer period using its own assumptions, before discounting all those cash flows back to today in dollar terms. On this basis, the DCF model indicates an estimated intrinsic value of about $339.68 per share. Compared with the recent share price of $332.77, the implied discount is around 2.0%, which points to Broadcom trading very close to this mode...
Earnings Call Insights: Samsara Inc. (IOT) Q4 2026 Management View CEO Sanjit Biswas described FY '26 as "an outstanding year of durable and efficient growth," highlighting $1.9 billion in ARR, up 30% year-over-year, and noted, "Our $432 million of net new ARR drove this performance, growing 21% year-over-year and demonstrating our ability to accelerate growth even as we operate at much larger sca...
Earnings Call Insights: Samsara Inc. (IOT) Q4 2026 Management View CEO Sanjit Biswas described FY '26 as "an outstanding year of durable and efficient growth," highlighting $1.9 billion in ARR, up 30% year-over-year, and noted, "Our $432 million of net new ARR drove this performance, growing 21% year-over-year and demonstrating our ability to accelerate growth even as we operate at much larger scale." Biswas emphasized momentum with large customers, stating, "We ended the year with $1.2 billion of ARR from our $100,000-plus ARR customers, an increase of 37% year-over-year and our second consecutive quarter of sequential acceleration." The company unveiled its first AI agent, the AI Safety Coach, with Biswas explaining it delivers "automated safety outcomes, providing real-time voice coaching in the cab, and personalized end-of-week coaching videos for workers." Biswas noted major customer wins in Q4, including Southern California Edison, Groundworks, and Harris County in Texas, and highlighted customer expansion, such as Estes, which "expanded in Q4 to add equipment monitoring, Asset Tags and connected asset maintenance." Biswas announced the retirement of Chief Product Officer Kiran Saker, with CTO John Bicket and SVP Johan Land assuming product leadership roles. CFO Dominic Phillips said, "Q4 was another quarter of accelerating growth and improved operating leverage," citing "31% year-over-year net new ARR growth in constant currency, the third consecutive quarter of sequential acceleration and the highest net new ARR growth in the past 8 quarters." Outlook Phillips provided guidance: "For Q1, we expect revenue to be between $454 million and $456 million, representing 24% year-over-year growth or 22% to 23% growth in constant currency. Non-GAAP operating margin to be 15%. And Non-GAAP EPS to be between $0.12 and $0.13." For full year FY '27, management expects "revenue to be between $1.965 billion and $1.975 billion, representing 21% to 22% year-over-year growth o...
JHVEPhoto/iStock Editorial via Getty Images The following segment was excerpted from the Nomura Value Fund Q4 2025 Commentary. Proceeds from the sale of Kenvue ( KVUE ) were used to purchase a position in Zoetis Inc. ( ZTS ), a leading global provider of animal health products that was spun out of pharmaceutical maker Pfizer Inc. ( PFE ) in 2013. Approximately two-thirds of Zoetis's revenue is gen...
JHVEPhoto/iStock Editorial via Getty Images The following segment was excerpted from the Nomura Value Fund Q4 2025 Commentary. Proceeds from the sale of Kenvue ( KVUE ) were used to purchase a position in Zoetis Inc. ( ZTS ), a leading global provider of animal health products that was spun out of pharmaceutical maker Pfizer Inc. ( PFE ) in 2013. Approximately two-thirds of Zoetis's revenue is generated by products for companion animals while the remainder comes from products for livestock. Zoetis produces a diversified range of products that are sold primarily to veterinarians, veterinary distributors, retail and ecommerce outlets, and livestock producers. Approximately 55% of the company's revenue is sourced in the US; its non-US revenue is sourced from many different countries around the world. The animal health industry is largely insulated from several drawbacks associated with the human pharmaceutical industry, such as product concentration, shorter brand lifecycles compared to human drugs, large revenue declines following patent expirations, sizable generics penetration, costly and unpredictable drug commercialization outcomes, the significant presence of third-party payors, and risks associated with product liability and government policy. Zoetis maintained consistently positive operational revenue growth over the past 16 years, largely in the mid- to high-single-digit range, even during the global financial crisis and the COVID-19 pandemic. Furthermore, the company had faster organic growth than the animal health market, which is expected to continue growing at a mid-single-digit pace. At the time of our initial purchase, Zoetis's shares were down 30% from their 2024 high, owing to concerns about the launch of a competing product in the dermatology segment, negative press around the alleged side effects of an osteoarthritis drug for dogs (along with an Food and Drug Administration (FDA) letter recommending a labeling update on potential adverse effects), an...
wdstock/iStock Editorial via Getty Images This year, growth stocks have fallen hard. Investors have taken any and all reasons as a signal to sell, with mounting worries on the state of the economy, the impact of AI, and rising geopolitical tensions. The depth of the recent crash, in my view, creates many compelling buying opportunities. Recent IPOs have been especially hard hit, and StubHub ( STUB...
wdstock/iStock Editorial via Getty Images This year, growth stocks have fallen hard. Investors have taken any and all reasons as a signal to sell, with mounting worries on the state of the economy, the impact of AI, and rising geopolitical tensions. The depth of the recent crash, in my view, creates many compelling buying opportunities. Recent IPOs have been especially hard hit, and StubHub ( STUB ), the ticketing platform, is no exception. Shares of StubHub went public last September at $23.50 per share; today, after falling more than 30% since the start of January alone, the stock trades at less than half of that price. The question for investors now is when will the bleeding in StubHub end? Data by YCharts I last wrote a sell article on StubHub in November, when the stock was trading around $19 per share. Since then, StubHub has fallen to less than half of that level, which absolutely warrants me to take a second look at the stock with fresh eyes. I still see many issues in this name: a competitive market, thin margins, and slowing growth. But at the same time, StubHub's valuation has also become more compelling after the crash, while the company also has clear business drivers that can propel the company into its next chapter. With all of these factors in mind, I'm upgrading the stock back to neutral. To me, at current share prices, StubHub has become a mixed bag of positive and negative catalysts. On the positive side for the company: StubHub is building a technology platform for Direct Issuance. Shifting away from its B2C and C2C roots, the company is planning to position its Direct Issuance (giving rights holders the ability to sell tickets directly on the StubHub platform) as a technology offering, which gives StubHub a capital-light means of expanding into a new market for fee-based income. Secular tailwinds for live events. The economy may be hurting, but the market for live events and experiences appears to continue growing, as more and more young consume...
US military investigators believe it is likely that US forces were responsible for an apparent strike on an Iranian girls’ school that killed scores of children on Saturday but have not yet reached a final conclusion or completed their investigation, two US officials told Reuters. Reuters was unable to determine more details about the investigation, including what evidence contributed to the te...
US military investigators believe it is likely that US forces were responsible for an apparent strike on an Iranian girls’ school that killed scores of children on Saturday but have not yet reached a final conclusion or completed their investigation, two US officials told Reuters. Reuters was unable to determine more details about the investigation, including what evidence contributed to the tentative assessment, what type of munition was used, who was responsible or why the US might have struck the school. US Defence Secretary Pete Hegseth on Wednesday acknowledged the US military was investigating the incident. Advertisement The officials, who spoke on condition of anonymity to discuss sensitive military matters, did not rule out the possibility that new evidence could emerge that absolves the US of responsibility and points to another responsible party in the incident. 01:36 Thousands attend funeral for victims of Iranian school bombing, the deadliest incident in Iran war Thousands attend funeral for victims of Iranian school bombing, the deadliest incident in Iran war Reuters could not determine how much longer the investigation would last or what evidence US investigators are seeking before the assessment can be completed.